Table 3.
Comparison Between Patients with IBD Who Had Stable/Improved Symptoms and Those with Worse Symptoms Post-LT
| Association | Stable/better post-LT (n=21) | Worse post-LT (n=6) | P-value |
|---|---|---|---|
| Sex | |||
| Males (n=20) | 16 | 4 | .63 |
| Females (n=7) | 5 | 2 | .63 |
| Diagnosis | |||
| UC (n=17) | 15 | 2 | .08 |
| CD (n=10) | 6 | 4 | .08 |
| Location | |||
| Left-sided | 2 | 0 | .43 |
| Pancolitis | 16 | 4 | .63 |
| Pouch | 2 | 2 | .14 |
| Terminal-ileum | 1 | 0 | .58 |
| Pre-LT IBD | |||
| Inactive | 13 | 5 | .32 |
| Active | 8 | 1 | .32 |
| Pre-LT maintenance therapy | |||
| None | 10 | 4 | .41 |
| 5-ASA | 12 | 1 | .08 |
| Azathioprine/prednisone | 1 | 1 | .32 |
| Infliximab | 1 | 0 | .58 |
| Post-LT immunosuppression | |||
| Tacrolimus/MMF | 15 | 4 | .82 |
| Tacrolimus/prednisone | 2 | 0 | .43 |
| Cyclosporine/MMF | 0 | 1 | .05 |
| Tacrolimus | 1 | 0 | .58 |
| Tacrolimus/cyclosporine | 1 | 0 | .58 |
| Cyclosporine | 0 | 1 | .05 |
| Tacrolimus/sirolimus | 1 | 0 | .58 |
| Tacrolimus/azathioprine/prednisone | 1 | 0 | .58 |
| Post-LT maintenance therapy | |||
| None | 10 | 0 | .03 |
| 5-ASA | 10 | 1 | .17 |
| Corticosteroids | 0 | 2 | .006 |
| Azathioprine | 1 | 0 | .58 |
| Methotrexate | 0 | 0 | N/A |
| Infliximab | 0 | 2 | .006 |
| Infliximab/cyclosporine | 0 | 1 | .05 |
| Outcome | |||
| Colorectal cancer | 1 | 1 | .32 |
| PTLD | 0 | 1 | .05 |
| Death | 0 | 1 | .05 |
5-ASA=5-aminosalicylic acid; CD=Crohn’s disease; IBD=inflammatory bowel disease; LT=liver transplantation; MMF=mycophenolate mofetil; PTLD=post-transplant lymphoma; UC=ulcerative colitis.